Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid CancerAlan L. Ho, James A. Fagin, José Miguel Domínguez et al.|New England Journal of Medicine|2013Cited by 825
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Eric J. Sherman et al.|New England Journal of Medicine|2020Cited by 766
Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic reviewScott A. Laurie, David G. Pfister, Alan L. Ho et al.|The Lancet Oncology|2010Cited by 394
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell CarcinomaSean M. McBride, Nancy Y. Lee, Eric J. Sherman et al.|Journal of Clinical Oncology|2020Cited by 393
American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatmentDavid C. Shonka, Gregory W. Randolph, Alan L. Ho et al.|Head & Neck|2022Cited by 110